Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:386390rdf:typepubmed:Citationlld:pubmed
pubmed-article:386390lifeskim:mentionsumls-concept:C0002600lld:lifeskim
pubmed-article:386390lifeskim:mentionsumls-concept:C0042665lld:lifeskim
pubmed-article:386390lifeskim:mentionsumls-concept:C0683149lld:lifeskim
pubmed-article:386390lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:386390lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:386390lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:386390lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:386390pubmed:issue4lld:pubmed
pubmed-article:386390pubmed:dateCreated1979-12-20lld:pubmed
pubmed-article:386390pubmed:abstractTextThe antidepressive effect of viloxazine (300 mg/d) was investigated during three weeks in 41 patients with depressive syndromes requiring drug-treatment against amitriptyline (150 mg/d), using a controlled double-blind design. Viloxazine differs from amitriptyline by selective inhibition of norepinephrine re-uptake, whereas amitriptyline acts also on serotonin re-uptake. Psychopathological changes were documented by means of the Hamilton Depression Rating Scale, the Bf-S (v. Zerssen), the AMDP-System, and videotaped recordings. Besides routine clinical-chemical tests, the serum concentrations of viloxazine and partly of amitriptyline were determined. Repeated EEG-recordings were evaluated by spectral analysis. The number of global responders and non-responders -- defined according to the final HDRS-scores -- was equally distributed between the two drug-groups. The AMDP-evaluation suggests that viloxazin has a somewhat more marked and more rapid effect on symptoms of retardation, whereas amitriptyline acts predominantly on depressive mood, disturbances of sleep and vital feelings. The EEG-profile of both drugs was similar to the spectral changes seen under tricyclic antidepressants, through only the viloxazine-induced changes reached statistical significance on the 10th and 20th day, the variability of the EEG-recordings being greater in the amitriptyline group. The viloxazine blood levels showed a remarkably low inter- and intraindividual variance. Steady state was reached at day 5 at the latest. Amitriptyline serum concentrations still increased between the 10th and the 21st day. The average blood concentration of viloxazine was higher in the responder- than in the non-responder-group.lld:pubmed
pubmed-article:386390pubmed:languageenglld:pubmed
pubmed-article:386390pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:386390pubmed:citationSubsetIMlld:pubmed
pubmed-article:386390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:386390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:386390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:386390pubmed:statusMEDLINElld:pubmed
pubmed-article:386390pubmed:monthJullld:pubmed
pubmed-article:386390pubmed:issn0031-7098lld:pubmed
pubmed-article:386390pubmed:authorpubmed-author:Müller-Oerlin...lld:pubmed
pubmed-article:386390pubmed:authorpubmed-author:RütherEElld:pubmed
pubmed-article:386390pubmed:issnTypePrintlld:pubmed
pubmed-article:386390pubmed:volume12lld:pubmed
pubmed-article:386390pubmed:ownerNLMlld:pubmed
pubmed-article:386390pubmed:authorsCompleteYlld:pubmed
pubmed-article:386390pubmed:pagination321-37lld:pubmed
pubmed-article:386390pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-H...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-D...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-A...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-M...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-F...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-M...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-E...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-A...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-P...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-M...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-C...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-A...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-D...lld:pubmed
pubmed-article:386390pubmed:meshHeadingpubmed-meshheading:386390-V...lld:pubmed
pubmed-article:386390pubmed:year1979lld:pubmed
pubmed-article:386390pubmed:articleTitleClinical profile and serum concentration of viloxazine as compared to amitriptyline.lld:pubmed
pubmed-article:386390pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:386390pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:386390pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:386390pubmed:publicationTypeControlled Clinical Triallld:pubmed